ArticleCommunications medicine2025
Progression-free survival for unresectable non-metastatic locally advanced pancreatic cancer after surgical microwave ablation plus durvalumab and tremelimumab: phase-2 non-randomized prospective clinical trial.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite significant advancements in cancer immunotherapy, survival outcomes remain poor in patients with pancreatic ductal adenocarcinoma.
methodsIn this early phase II clinical trial, we evaluated the combined effects of immunotherapy with dual immune checkpoint inhibitors durvalumab and tremelimumab, local tumor ablation with microwave energy, and gemcitabine on progression-free survival in twelve patients with non-metastatic unresectable locally advanced pancreatic adenocarcinoma. Single-cell transcriptomics and T cell receptor profiling were used to characterize the tumor microenvironment and peripheral blood immune cell repertoire.
resultsHere we show that from these twelve patients (median progression-free survival = 8.9 months, 95% confidence interval 3.2-18.4), eight patients received the combination therapy (median progression-free survival of 11.2 months, 95% confidence interval 4.0-18.4). One of these eight patients experiences grade 5 toxicity. Using single-cell transcriptomics and T cell receptor profiling, we characterize the tumor microenvironment and peripheral blood immune cell repertoire of six patients, of which three patients contain paired samples before and after the start of immunotherapy. We find substantial overlap in T cell receptors and CD8-Temra cells in the tumor microenvironment and in peripheral blood. Integration of the single-cell dataset with an independent bulk transcriptome cohort reveals that a high CD8-Temra gene signature is associated with improved overall survival. While there are interesting trends, T cell receptor-related metrics do not show statistically significant correlations with progression-free survival in this dataset.
conclusionsThese findings suggest that CD8-Temra cells may serve as potential biomarkers and therapeutic targets for immunotherapy efficacy in pancreatic ductal adenocarcinoma, pending validation in larger cohorts. We hypothesize that local tumor ablation may enhance tumor immunogenicity and systemic anti-tumor responses, supporting their integration into future treatment strategies. Future studies with larger cohorts are needed to validate these findings and optimize treatment protocols for wider clinical applicability.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.